**Supplemental Table S2.** Study treatment disposition (ITT population)

|  |  |  |  |
| --- | --- | --- | --- |
| **Number of subjects****N (%)** | **Total****n=59** | **Part 1 afuresertib dose levels** | **Part 2 group** |
| **Total phase I n-29** | **Dose level 1****50mg afuresertib****n=4** | **Dose level 1.5****75mg afuresertib****n=4** | **Dose level 2****100mg afuresertib****n=6** |  **Dose level 3****125mg afuresertib****n=12** | **Dose level 4****150mg afuresertib****n=3** | **Total Part 2****n=30** | **Cohort A****(treated at dose level 3) 125mg afuresertib****n=28** |
| P**rimary reason for treatment discontinuation** | 10 (16.9) | 4 (13.8) |  |  |  |  |  | 6 (20) | 6 (21.4) |
| Adverse Event | 2 (50) | 0 | 2 (33) | 0 | 0 |
| Progressive Disease (RECIST) | 35(59.3) | 17 (58.6) | 2 (50) | 3 (75) | 1 (16.7) | 8 (66.7) | 3 (100) | 18 (60) | 6 (21.4) |
| Symptomatic deterioration/Clinical Progression | 8(13.6) | 4 (13.8) | 0 | 1 (25) | 1 (16.7) | 2 (16.7) | 0 | 4(13.3) | 4(14.3) |
| Investigator Opinion | 1 (1.7) | 1 (3.4) | 0 | 0 | 0 | 1 (8.3) | 0 | 0 | 0 |
| Withdrawal of consent | 2 (3.4) | 2 (6.9) | 0 | 0 | 1 (16.7) | 1 (8.3) | 0 | 0 | 0 |
| Unknown | 2 (3.4) | 1 (3.4) | 0 | 0 | 1 (16.7) | 0 | 0 | 1 (3.3) | 0 |